Stock LSPR LARR HEALPAR
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News LARR HEALPAR

Equities

LSPR

US51724W1071

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Larkspur Acquisition Completes Merger With ZyVersa Therapeutics
MT
ZyVersa Therapeutics Inc. and Larkspur Health Acquisition Corp. Close Business Combination; ZyVersa Expected to Begin Trading on Nasdaq December 13, 2022 (Ticker "ZVSA")
PR
Larkspur Health Acquisition Corp.(NasdaqGM:LSPR) dropped from NASDAQ Composite Index
CI
Larkspur Health Acquisition Corp. announced that it has received $8.635 million in funding
CI
ZyVersa Therapeutics, Inc. completed the acquisition of Larkspur Health Acquisition Corp. from Larkspur Health LLC, A.G.P. / Alliance Global Partners Corp. and others in a reverse merger transaction.
CI
LARKSPUR HEALTH ACQUISITION CORP. : Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Larkspur Health Acquisition Corp. has Changed its Name to ZyVersa Therapeutics, Inc
CI
ZyVersa Therapeutics' CEO, Stephen C. Glover, and CCO, Karen A. Cashmere, Are Invited Speakers at the 4th Inflammasome Therapeutics Summit
PR
SEC Declares Form S-4 Registration Statement "Effective" for Proposed Business Combination of Larkspur Health Acquisition Corp., Inc. with ZyVersa Therapeutics, Inc.
PR
LARKSPUR HEALTH ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
Larkspur Health Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
ZyVersa Therapeutics' CEO, Stephen C. Glover, Is Invited Speaker at BioFlorida 2022 Annual Conference
PR
Larkspur Health Acquisition Refiles Registration Statement for Business Combination Agreement With ZyVersa Therapeutics
MT
ZyVersa Therapeutics and Larkspur Health Acquisition Corp. Announce Business Combination, Interim Financing and PIPE Investment Update
PR
Data Published in Frontiers in Molecular Neuroscience Demonstrate That ZyVersa's Inflammasome ASC Inhibitor, IC 100, Is Effective in Reducing Brain Inflammation in a Preclinical Model of Aging
PR
LARKSPUR HEALTH ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
Larkspur Health Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
Larkspur Health Acquisition Corp. Files Registration Statement on Form S-4 Regarding the Proposed Business Combination with ZyVersa Therapeutics
PR
ZyVersa's Proprietary Inflammasome ASC Inhibitor's Differentiated Mechanism of Action Featured in Translational Research Paper
PR
Larkspur Health Acquisition : ZyVersa Therapeutics to Become a Publicly Traded Biopharma Company via Merger with Larkspur Health Acquisition Corp - Form 8-K
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LSPR Stock
  4. News LARR HEALPAR